title: Diagnostic value of circulating miR-21: An update meta-analysis in various cancers and validation in endometrial cancer.
abstract: MiR-21 has been identified as one of the most common proto-oncogenes. It is hypothesized that up-regulated miR-21 could be served as a potential biomarker for human cancer diagnosis. However, inconsistencies or discrepancies about diagnostic accuracy of circulating miR-21 still remain. In this sense, miR-21's diagnostic value needs to be fully validated. In this study, we performed an update meta-analysis to estimate the diagnostic value of circulating miR-21 in various human cancers. Additionally, we conducted a validation test on 50 endometrial cancer patients, 50 benign lesion patients and 50 healthy controls. A systematical literature search for relevant articles was performed in Pubmed, Embase and Cochrane Library. A total of 48 studies from 39 articles, involving 3,568 cancer patients and 2,248 controls, were included in this meta-analysis. The overall sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and area under the curve (AUC) were 0.76 (0.71-0.80), 0.82 (0.79-0.85), 4.3 (3.6-5.1), 0.29 (0.24-0.35), 15 (11-20) and 0.86 (0.83-0.89), respectively. In the validation test, the expression levels of serum miR-21 were significantly higher in benign lesion patients (p = 0.003) and endometrial cancer patients (p = 0.000) compared with that of healthy controls. Endometrial cancer patients showed higher miR-21 expression levels (p = 0.000) compared with benign lesion patients. In conclusion, the meta-analysis shows that circulating miR-21 has excellent performance on the diagnosis for various cancers and the validation test demonstrates that serum miR-21 could be served as a novel biomarker for endometrial carcinoma.
authors.affiliation: Medical Science Laboratory, the Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi 545005, China.
authors.forename: Yun
authors.initials: Y
authors.lastname: Gao
authors.affiliation: Medical Science Laboratory, the Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi 545005, China.
authors.forename: Meiyu
authors.initials: M
authors.lastname: Dai
authors.affiliation: Medical Science Laboratory, the Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi 545005, China.
authors.forename: Haihua
authors.initials: H
authors.lastname: Liu
authors.affiliation: Medical Science Laboratory, the Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi 545005, China.
authors.forename: Wangjiao
authors.initials: W
authors.lastname: He
authors.affiliation: Medical Science Laboratory, the Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi 545005, China.
authors.forename: Shengzhang
authors.initials: S
authors.lastname: Lin
authors.affiliation: Department of Thoracic Surgery, the Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi 545005, China.
authors.forename: Tianzhu
authors.initials: T
authors.lastname: Yuan
authors.affiliation: Department of Haematology, the Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi 545005, China.
authors.forename: Hong
authors.initials: H
authors.lastname: Chen
authors.affiliation: Medical Science Laboratory, the Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi 545005, China.
authors.forename: Shengming
authors.initials: S
authors.lastname: Dai
mesh_terms: D000465:Algorithms; D019540:Area Under Curve; D014408:Biomarkers, Tumor / Q000097:blood; D016022:Case-Control Studies; D016889:Endometrial Neoplasms / Q000097:blood / Q000235:genetics*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000097:blood*; D009369:Neoplasms / Q000097:blood / Q000235:genetics*; D016017:Odds Ratio; D011786:Quality Control; D012680:Sensitivity and Specificity
chemical_list: D014408:Biomarkers, Tumor; C524940:MIRN21 microRNA, human; D035683:MicroRNAs
keywords: cancers; diagnosis; endometrial carcinoma; meta-analysis; miR-21